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Hepatitis B affects approximately 350 million people
worldwide, and an estimated 1.25 million people in the
United States. Although most people infected with the virus
do not develop significant hepatic disease from hepatitis B,
15–40% will develop serious complications. These
complications include cirrhosis, the development of
hepatocellular carcinoma , and hepatic decompensation.
Patients with renal failure have increased risk of acquiring the
virus through blood transfusions and contact with bodily
fluids at hemodialysis centers, and of developing
complications from hepatitis B virus infection. Renal
transplant patients are at increased risk for exacerbations of
hepatitis B with immunosuppression. Thus, it is crucial for the
nephrologist to have a clear understanding of the natural
history and treatment of hepatitis B, both pre- and post-renal
transplant.
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Hepatitis B affects approximately 350 million people world-
wide, and an estimated 1.25 million people in the United
States. Although most people infected with the virus do not
develop significant hepatic disease from hepatitis B, 15–40%
will develop serious complications. These complications
include cirrhosis, the development of hepatocellular carcino-
ma (HCC), and hepatic decompensation. Patients with renal
failure have increased risk of acquiring the virus through
blood transfusions and contact with bodily fluids at
hemodialysis (HD) centers, and of developing complications
from hepatitis B virus (HBV) infection. Renal transplant
patients are at increased risk for exacerbations of hepatitis B
with immunosuppression. Furthermore, patients with
chronic hepatitis B may develop renal disease secondary to
HBV infection. Thus, it is crucial for the nephrologist to have
a clear understanding of the natural history and treatment of
hepatitis B, both pre- and post-renal transplant.
VIROLOGY
Hepatitis B is a hepadnavirus – a double stranded DNA virus.
Its life cycle begins with infection of the hepatocyte. Once
inside the nucleus of the hepatocyte, the HBV DNA
polymerase starts repairing the gap in the positive strand to
form a covalently closed circular DNA (cccDNA), which is
the form in which HBV persists in host cells and serves as the
template for the pregenomic RNA. The viral mRNA by host
RNA polymerase is then translated in the cytoplasm to
produce HBV surface, core, polymerase, and X proteins. In
the cytoplasm, viral capsids are assembled, incorporating
genomic viral RNA with a molecule of HBV DNA
polymerase. The HBV DNA polymerase has a reverse
transcriptase function that catalyzes the synthesis of the
negative strand of DNA, which, in turn serves, as the tem-
plate for the positive strand synthesis. These nucleocapsids
can go back to the nucleus and be recycled as additional
cccDNA molecules but the majority of them are transported
via the endoplasmic reticulum to form mature virions that
are subsequently released into the pericellular space.1,2 Thus,
cccDNA is maintained both by new virions penetrating the
cell and being converted by host cell mechanisms to cccDNA
and by intracellular viral genomes being transported back to
the nucleus. Most anti-viral therapies do not target cccDNA,
which partly explains why HBV DNA levels rapidly rise once
treatment is stopped.
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HBV IN THE RENAL PATIENT
Both the prevalence and incidence of HBV among patients
with end-stage renal disease has declined in the United States
and in Europe. This is largely the result of the introduction of
universal precautions, screening of the blood supply, the use
of erythropoietin and its analogs with resultant decreased
transfusion requirements, and the practice of segregating
hepatitis B surface antigen (HBsAg) (þ ) patients from those
who are HBsAg (). The CDC estimates that the prevalence
of HBsAg (þ ) patients among HD patients has declined
from 7.8 to 0.9%, with an estimated incidence of disease in
2000 of 0.05%.3
Despite these efforts, viral transmission has been reduced
but not eliminated in HD patients. Transmission likely occurs
through contamination of multi-dose vials and other occult
parenteral exposures. All patients on HD should be screened
for HBV and vaccinated if not immune. The optimal
screening regimen, however, is unclear. In most centers, this
is done by testing for HBsAg. However, a recently published
population-based study suggests that hepatitis B is 4–5 times
more prevalent in a North American HD population than is
suggested by relying on standard HBsAg testing.4 Patients
who are negative for HBsAg and who have HBV DNA have
occult HBV. Occult HBV is a poorly defined clinical entity
but traditionally describes patients who have HBV DNA but
are HBsAg (). It includes patients who are HBcAb (þ ),
known as seropositive, and those who are HBcAb (),
known as seronegative. As untreated hepatitis B has serious
implications, these authors propose that all HD patients be
screened with hepatitis B DNA testing. It should be
emphasized, though, that this finding has yet to be confirmed
and that testing all patients on HD for HBV DNA would be
very costly. A more cost-effective strategy might be testing
those patients who test positive for HBcAb, as it is established
that occult HBV is much more common among HbcAb (þ )
patients, compared to HbcAb () patients5,6 At the current
time, there is no conclusive data to recommend further
screening in HBsAg () patients.
Hepatitis B is associated with high mortality rates among
renal patients. Although hepatitis C has been the biggest
concern among renal patients owing to the large numbers of
people affected, hepatitis B is associated with a higher
mortality risk. In a study of 286 renal transplant patients,
liver-related death was the most common cause of death in
HBV-positive patients, whereas HCV-positive patients were
more likely to die of a cardiovascular event.7 Additionally,
HBsAg seropositivity was found to be an independent and
significant risk factor for graft failure following kidney
transplantation.8
In addition to patients with renal disease and hepatitis B
infection, there are patients with hepatitis B who have renal
disease as a result of the HBV virus itself. Hepatitis B-induced
renal disease encompasses a variety of clinical entities that
manifest with varying degrees of severity. Most of these
conditions are mediated by the deposition of immune
complexes, although a variety of pathologic mechanisms
have been described.9 In the pediatric population, HBV-
associated nephropathy is typically asymptomatic and
detected on routine screening. In adults, the most common
manifestations are proteinuria and the nephrotic syndrome.
It is not clear which patients with HBV are more likely to
develop renal disease. The natural history of HBV-induced
renal disease is also not very well established. It is known that
some cases resolve spontaneously, and that some cases of
remission are associated with HBeAg seroconversion. Ster-
oids do not seem to be of benefit in HBV-induced renal
disease.10
PATIENT POPULATIONS
Chronic hepatitis B is defined by the presence of HBsAg for
more than 6 months with histologic changes on liver biopsy
or persistently elevated alanine aminotransferase (ALT). We
divide HBV patients into two groups, e antigen (HBeAg)
positive and those that are e antigen negative (usually with
antibody to e antigen, HBeAb). Patients who are HBeAg
positive have active replication with wild-type virus, with
high levels of circulating HBV DNA. Those who are HBeAg
negative can further be classified into the actively replicating
‘pre-core’ mutants, and those who are quiescent, previously
known as the ‘healthy or inactive carrier’. Pre-core mutant
HBV has a mutation in the pre-core region or the basic core
promoter region of the HBV DNA genome that allows
replication without e antigen production. These patients tend
to have fluctuating levels of HBV DNA in their blood and are
more common in Southern Europe, the Middle East, and
Asia, whereas the e antigen-positive patients are typically
found in North America and Northern Europe. HBe antigen-
negative patients with pre-core mutations tend to have a
worse prognosis and poorer response to therapy than e
antigen-positive patients.
The term ‘inactive or healthy carrier state’ is a misnomer.
Although patients with HBsAg in their blood and normal
ALT tend to have little evidence of inflammation on liver
biopsy, low levels of DNA in the serum, and a better
prognosis, they do have both circulating DNA and cccDNA
and, therefore, are not ‘inactive’. These patients can have
progressive liver disease and/or HCC. However, currently
there is no evidence to support treatment with anti-viral
therapy owing to low-level replication that cannot be
suppressed with current therapy.
THERAPY FOR HEPATITIS B
There are currently five medications approved for the
treatment of hepatitis B – interferon alfa-2b, pegylated
interferon alfa 2a, lamivudine, adefovir, and entecavir. The
arsenal of therapeutic options, diverse patient population,
and lack of clear guidelines makes the treatment of hepatitis
B a daunting task.
Goals of therapy
The goals of therapy in HBV depend on the degree of
liver injury and state of replication. Suppression of viral
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replication and prevention of the development of fibrosis are
the primary goals for any patient. Seroconversion from
HBsAg positivity to HBsAb positivity is the rarely achieved,
but optimal goal of therapy. It is unclear whether this
represents complete and permanent viral clearance or cure,
however. For those patients with wild-type virus (HBeAg
positive), an important end point is seroconversion to HBeAb
positivity, which tends to lead to a durable response with low
levels of HBV DNA and normal ALT levels. For pre-core
mutants who do not produce HBeAg, HBV DNA levels need
to be followed to assess response to therapy.
THERAPEUTIC AGENTS
Interferons
Interferon has the longest track record in HBV treatment and
has immunomodulatory, anti-fibrotic, and anti-viral effects.
However, interferon is parenterally administered and has
significant side effects including an influenza-like syndrome,
myelosuppression, fatigue, and depression. Pegylated inter-
feron, created by attaching a polyethylene glycol multimer to
interferon, improves the pharmacokinetics of the drug, and
allows for a weekly dosing schedule and reliable drug levels.
Pegylated interferon is associated with a 30–35% HBeAg
seroconversion rate, compared to 16–20% with standard
interferon.
In two recently published, multi-center, randomized
controlled trials in both HBeAg-positive and -negative
patients, pegylated interferon was shown to be more effective
than lamivudine alone at reducing HBV DNA as well as
inducing HBsAg and HBeAg seroconversion. In both studies,
the combination of pegylated interferon with lamivudine was
more effective than lamivudine alone but not better than
pegylated interferon monotherapy.11,12 The increased con-
venience and efficacy of pegylated interferon has virtually
eliminated the use of standard interferon in HBV. Of note,
patients with renal disease (broadly defined as creatinine
values 1.5 times the upper limit of normal or greater than
1.5 mg per deciliter) were excluded from these studies and
there is very limited data supporting the use of interferon
therapy in patients with renal disease. Furthermore, inter-
feron is not used in the post-transplant setting owing to its
association with acute rejection.13 Interferon may have a role
in the treatment of hepatitis B-induced membranous
nephropathy. Three months of interferon therapy has been
shown to be effective in eliminating proteinuria in a small
number of patients.14
Lamivudine
Lamivudine is a cytosine analog that inhibits HBV reverse
transcriptase. Lamivudine has been widely used in HBV,
particularly for renal patients, given its efficacy and
tolerability. It can also be used effectively in patients who
have been treated with interferon previously. It is adminis-
tered once daily, typically at a dose of 100 mg, and is generally
well tolerated and safe in long-term studies. Side effects,
when they occur, are generally mild and include headache,
nausea, and vomiting. Dosage is reduced in patients with
some degree of renal insufficiency according to their
creatinine clearance (see Table 1). Lamivudine has been
shown to induce both seroconversion and a histological
response in addition to reducing HBV DNA. Data on
lamivudine use in patients with renal disease is limited to
uncontrolled studies on small numbers of patients. However,
several studies have shown lamivudine to be effective at both
reducing HBV DNA levels and normalizing ALT in patients
post-renal transplant.15,16
However, when used in the post-renal transplant setting,
lamivudine response rates have been somewhat lower than
those seen in patients without renal disease – with up to a
45% rate of non-response or relapse after 36 months of
therapy.17
Unfortunately, duration of oral anti-viral therapy is
related to both the likelihood of response and to the
development of resistance. Although HBeAg seroconversion
rates of 21, 29, and 40% at 1, 2, and 3 years, respectively18 are
encouraging, these results are tempered by resistance rates,
which are 14–20% at 1 year and 69% at 5 years.19
Furthermore, use of lamivudine in HBeAg-negative patients
is associated with more rapid resistance – 60% at 4 years.20
There is also data from liver transplant patients that suggest
that resistance develops more quickly in the post-transplant
setting.21
The role of lamivudine is evolving for patients with HBV-
induced renal disease. In a recent study, HBsAg (þ ) patients
with membranous nephropathy treated with lamivudine
therapy for 1 year had reduced proteinuria and decreased
HBV DNA compared to historic control patients taken
from the pre-lamivudine era.22 Current recommendations
Table 1 | Dosage adjustment of drugs for hepatitis B in patients with renal insufficiency
CrClX50 (ml/min) CrCl 30-o50 (ml/min) CrCl 10-o30 (ml/min) CrClo10 (ml/min) HD
Lamivudine 100 mg p.o. q.d. 100 mg first dose then
50 mg p.o. q.d.
100 mg first dose then
25 mg p.o. q.d.
35 mg first dose then
15 mg p.o. q.d.a
35 mg first dose then
10 mg p.o. q.d.
Adefovir 10 mg p.o. q.d. 10 mg po every 48 hours 10 mg po every 72 hours No dosing recommended 10 mg every 7 days
Entecavir 0.5 mg p.o. q.d. 0.25 mg p.o. q.d. 0.15 mg p.o. q.d. 0.05 mg p.o. q.d. Administer after HD
Entecavir in Lamivudine
refractory- patients
1 mg p.o. q.d. 0.5 mg p.o. q.d. 0.3 mg p.o. q.d. 0.1 mg p.o. q.d. Administer after HD
HD, hemodialysis.
aLamivudine should be dosed at 35 mg initially and then 10 mg daily for patients with CrClo15 ml/min.
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generally are to treat HBV– induced renal disease with
indefinite oral anti-viral therapy aimed at sustained suppres-
sion of viral replication. This may, however, require combina-
tion therapy to prevent development of viral resistance.
Lamivudine resistance is a major clinical problem caused
by a mutation in the YMDD locus of the HBV DNA
polymerase. In a study of 29 patients with rising HBV DNA
post-renal transplant, lamivudine therapy was associated
with detectable resistance in 48.3% of patients during a mean
follow-up period of 68.7 months, all of whom showed
YMDD mutations. Resistance was not related to patient
demographics, HBeAg status, seroconversion rates, or
genotype. Of these patients, 78.6% who developed the
YMDD mutation had a flare of their hepatitis, characterized
by an increase in ALT, but this was transient in 36% and
chronic in 54.5%. One patient suffered an episode of hepatic
decompensation, but all survived.23
Lamivudine has also been studied in patients pre-renal
transplant. Lamivudine was given to three different patient
populations: those who were HBV DNA-positive pre-renal
transplant, those who were HBV DNA-negative post-renal
transplant, and patients post-renal transplant with evidence
of hepatitis. It was shown that lamivudine use before
transplant was associated with lower rates of reactivation of
hepatitis B than its use post-transplant in response to
evidence of hepatitis.24 Survival post-transplant was im-
proved in patients who were treated with lamivudine pre-
transplant in a preemptive strategy.25 This data highlights
a lower threshold for treatment of HBV before kidney
transplantation to improve post-transplant outcomes.
In our practice, the high rate of resistance coupled with
the availability of other therapeutic options limits the use of
lamivudine to a few clinical scenarios, specifically, acute liver
failure owing to hepatitis B, pregnancy, prophylaxis against
the reactivation of hepatitis B in the setting of immuno-
suppression, most commonly chemotherapy, and pre- and/or
post-renal transplant for patients with low or negative viral
loads pre-transplant. More frequently, lamivudine is used in
conjunction with other anti-virals such as adefovir as
resistance is so common. The prevalence of lamivudine
resistance underscores the need for other therapies and the
further study of combination therapy.
Adefovir
Adefovir dipivoxil is a phosphonate nucleotide analog of
adenosine, which competitively binds HBV DNA polymerase
and serves as a chain terminator. Adefovir is used at a dose of
10 mg daily and its utility has been shown in naive HBeAg
positive and negative patients, lamivudine-resistant patients,
patients co-infected with HIV, and in the post-liver
transplant setting.26,27
In studies of patients who are naive to HBV therapy,
adefovir has been shown to reduce HBV DNA levels to
undetectable levels and normalize ALT in 21 and 48% of
patients studied, respectively. Forty-eight weeks of adefovir
was associated with a 12% HBeAg seroconversion rate.28
More importantly, two recent studies have looked at the use
of adefovir in lamivudine-resistant HBV in both compen-
sated and decompensated liver disease. Patients with the
YMDD mutation were randomized to lamivudine plus
placebo or 10 mg of adefovir for 52 weeks. Patients with
compensated HBV experienced a significant decline in HBV
DNA levels and normalized ALT, (85 and 31%) respectively,
with adefovir compared to 11 and 6% of those patients given
lamivudine plus placebo. In decompensated patients, the use
of adefovir not only resulted in a statistically significant
difference in HBV DNA levels and ALT levels, but, more
importantly, an overall clinical improvement as measured by
the Child Turcotte Pugh (CTP) score.29 Other studies have
confirmed these results and shown similar effect of
lamivudine plus adefovir to adefovir alone, raising the
suggestion that the continuation of lamivudine might not
add any benefit.30 However, it is likely that adefovir resistance
can be delayed or eliminated when lamivudine is used in
combination with adefovir owing to a lack of any cross-
resistance between the two drugs. Although patients with
significant renal disease were excluded from these studies,
significant increases in creatinine were not seen on adefovir
therapy.
Unfortunately, though adefovir is also effective at inhibit-
ing HBV viral replication in HBeAg-negative patients, the
effect is transient and viral rebound occurs when treatment is
stopped. In one study, patients received adefovir for 144
weeks with excellent viral inhibition, low rates of resistance,
and minimal side effects but near universal relapse when the
drug was stopped after only 48 weeks of therapy.31 These
results underscore the fact that optimal duration of therapy
in HBeAg-negative patients is not known. Resistance to
adefovir has been reported in 5.9% of HBeAg () patients
after 144 weeks of therapy when used as monotherapy.32
The use of adefovir in patients with renal disease has been
limited by concern for potential renal side effects. In animal
studies, renal toxicity, characterized by a tubular nephropathy
and elevated creatinine, is the dose-limiting side effect. These
changes developed, however, at doses 3–8 times greater than
the recommended dose for humans, which is 10 mg daily,
and at higher doses (X30 mg/day) in HIV and HBVþ
patients. At the dose of 10 mg, however, significant renal side
effects have not been seen. So, though patients should have
their renal function monitored while on adefovir, it has been
shown to be safe to use in renal patients.33 Additionally,
adefovir has been studied in patients with lamivudine-
resistant HBV and renal disease, and has been shown to be
both safe and efficacious in this population.34 Adefovir
dosing needs to be dose adjusted in patients on HD (See
Table 1).
Entecavir
Entecavir is a guanosine analog that inhibits HBV DNA
polymerase at both the priming and elongating steps (of both
positive and negative strands) of DNA synthesis. It is 30 times
more potent than lamivudine in suppressing viral replication.
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In multi-center, double-blind randomized trials comparing
entecavir to lamivudine in both HBeAg positive and negative
patients, entecavir was shown to result in larger reductions in
HBV DNA than lamivudine. At a dose of 0.5 mg daily, 83% of
patients treated with entecavir had undetectable DNA
compared to 58% of those treated with lamivudine.35 In
recently published data of HBeAg (þ ) patients, 72% of those
on 0.5 mg of entecavir experienced histologic improvement,
compared to 62% of those on lamivudine (P¼ 0.0085) and
69% had undetectable HBV DNA levels, compared to 38% in
the lamivudine group (Po0.0001). HBeAg seroconversion
rates, however, of 21% with entecavir and 18% with
lamivudine were not significantly different.36 In HBeAg ()
patients, 70% had histologic improvement and 91% had
undetectable HBV DNA patients in the entecavir group
compared to 61% (P¼ 0.0143) and 73% (Po0.0001),
respectively, of those on lamivudine.37 Entecavir at a higher
dose of 1 mg/day has been studied in lamivudine-resistant
patients with 55% of the entecavir group experiencing
histologic improvement compared to 28% of the group
that continued on lamivudine (Po0.0001). Resistance to
entecavir is very low, but was seen in over 7% of the
lamivudine-resistant patients treated with entecavir for
1 year, making it unlikely to be the drug of choice as a
monotherapy in this situation. A randomized trial of
entecavir and adefovir is currently underway in patients
with decompensated liver disease.
The potential advantage to entecavir is its safety profile,
particularly in renal patients. Although the dose of entecavir
needs to be adjusted for patients with renal disease (see
Table 1), there is no known renal toxicity of the drug itself.
Long-term resistance remains undefined with entecavir, and
it needs to be taken on an empty stomach, separated from
food and other drugs by 2 h.
DRUGS IN DEVELOPMENT
Tenofovir, a cousin of adefovir, has anti-HBV activity, is
currently FDA-approved for HIV, and is in Phase III trials for
HBeAg-positive and HBeAg-negative HBV. Tenofovir has
been studied in several small, non-randomized studies. It is
often used in HIV/HBV co-infected patients, but has been
used in mono-HBV-infected patients as well. Emtricitabine
(FTC) is a cytosine nucleoside analog that is also active
against HBV and is entering phase II and III trials including
combination trials with tenofovir. In a study of 30 HBeAg
(þ ) patients, 48 weeks of adefovir plus emtricitabine was
associated with a median decrease of 3.48log10 copies/ml
compared to a median drop of 2.22log10 copies/ml in the
group on adefovir monotherapy (Po0.01).38 Given its
structural similarity to lamivudine, there is concern about
cross-resistance in patients with YMDD mutant virus.
Telbivudine (Ldt) is another nucleoside with specific
activity against HBV. In early studies, this drug has been
shown to have an excellent safety profile and to be effi-
cacious at reducing HBV DNA levels and is also in Phase III
studies.
TREATMENT ALGORITHMS
Our approach to classifying HBV patients is outlined in
Figure 1. All patients with HBsAg should have HBV DNA
levels, HBeAg, HBeAb, and alpha-fetoprotein checked.
Additionally, all patients should have hepatic imaging at
regular intervals (every 6–12 months) to screen for HCC.
Patients who are HBeAg positive should be considered as
candidates for anti-viral therapy (see Figure 2). Traditionally,
only patients with high levels of HBV DNA (4105 copies/ml)
and abnormal ALT levels were considered to be treatment
candidates, but this threshold has been called into question
recently. It is known that HBV DNA levels o105 copies/ml
can be associated with significant intrahepatic HBV DNA and
cccDNA levels. Recently published data suggest that HBV
DNA levels 4104 copies/ml is a risk factor for developing
HCC, independent of HBeAg, ALT levels, and the presence of
cirrhosis.39 Additionally, patients who are HBsAg () with
undetectable HBV DNA by hybridization who have devel-
oped HCC and cirrhosis have been found to have HBV DNA
when checked by polymerase chain reaction.40–42 In sum-
mary, the threshold HBV DNA level associated with liver
disease is not known and patients with o105 copies/ml may
still be at risk for progressive liver disease. Recently published
treatment guidelines by Keefe et al.43 have recommended
HBV DNA testing by polymerase chain reaction, and for
patients with o105 copies/ml and normal ALT levels
HBsAg (+)
HBeAg (+) HBeAg (−)
High VL
(104 copies/ ml)
Active HBV
Low VL104 copies/ml
Non-replicative
Previous 'healthy carrier'
High VL 104 copies/ml
'Pre-core mutant'
Figure 1 | Classification of patients with hepatitis B infection.
HBsAg (+)
Check HBV DNA, HBeAg,
HBeAb, AFP
HBeAg (+), high HBV DNA
 (>104copies/ml or > 1900 IU) HBeAg (−)
Consider starting anti-viral therapy
particularly if ALT is high or biopsy
reveals significant inflammation or fibrosis 
Decision to start therapy
will depend on HBV DNA 
levels (see Figure 3)
Figure 2 | Diagnostic and treatment approach to a patient with
hepatitis B infection.
Kidney International (2006) 70, 1897–1904 1901
SK Olsen and RS Brown Jr: Hepatitis B treatment m i n i r e v i e w
consideration of performing a liver biopsy to assess histology.
It should be noted, however, that patients with normal ALT
have never been studied adequately in clinical trials. Further
data to support a low threshold for biopsy in patients with
renal disease arises from studies showing lower transaminases
in patients with renal disease despite active inflammation on
liver biopsy.44 Those who are e antigen negative with high
levels of DNA should also be considered potential candidates
for therapy. (See Figure 3) At our center, these patients would
be recommended to have a liver biopsy to further stratify
their risk for developing chronic liver disease, but some
centers would opt to treat without a biopsy if HBV DNA was
greater than 104 copies/ml. We feel that HBeAg-negative
patients pre-renal transplant, with little inflammation on
biopsy may benefit from a strategy of observation until closer
to kidney transplantation as continuous therapy is required,
which would increase the likelihood of development of
resistance. Certainly those with lower levels (103–104 copies/
ml) of circulating DNA should also be considered for liver
biopsy to further evaluate the degree of hepatic inflammation
before deciding on treatment for hepatitis B. Patients with
p103 copies/ml are not candidates for current anti-viral
therapy in the absence of immunosuppression. After
transplant, all patients should be treated with lamivudine
or lamivudine plus adefovir until further data on entecavir in
the post-transplant setting is available to prevent viral
reactivation and flares.
VACCINATION
Treatment of hepatitis B would be obviated if everyone were
vaccinated. Vaccination is currently required for all children
in the US. Additionally, vaccination is recommended for all
patients with chronic renal disease, patients on HD, health
care workers, and sexually active individuals with multiple
partners. Vaccines are administered in a series of three shots
over 6 months and induce antibodies that will neutralize
HBsAg in 495% of people. Success rates of vaccination in
HD patients, however, is significantly lower, estimated to be
50–60%, owing to immune system depression related to
uremia.45,46 It is well established that vaccine success is
inversely related to the degree of renal dysfunction such that
an ‘earlier is better strategy’ should be employed in
vaccinating patients with renal disease.47 Many different
strategies have been looked at to improve vaccination success
in HD patients such as administering the vaccine more often,
intra-dermal administration, and coadministration with
different agents such as erythropoietin and interluekin-
2.48,49 Recent data suggest that a reinforced administration
schedule of every 2 weeks with intradermal injection of 20 mg
of Energix-Bs recombinant vaccine results in a 96.9%
seroconversion rate after 1 year with a peak HBsAb titer at
3.971.7 months. This approach is also reported to be cost
effective.50 There are also efforts to improve the vaccine itself.
A recently published study looked at HB-AS04, a vaccine for
hepatitis B that uses an adjuvant system to booster its
immunogenicity. The addition of an adjuvant system, AS04,
which is composed of aluminum salt and a specific form of
lipid A, results in increased production of cytokines, and a
more robust immune response. In a study of 165 patients
with renal disease (defined as creatinine clearance p30 ml/
min), use of the Hb-AS04 vaccine resulted in 91% response
rate (defined as anti-HBsX10 mIU/ml) compared to 84% of
those given conventional vaccine (in this case, EngerixTM).
These differences were persistent and were seen at 36 months
follow-up with 73% of those who received HB-AS04
maintaining protective anti-HBs compared to 52% of those
who received standard vaccine. Additionally, the use of the
HB-AS04 vaccine was associated with more rapid develop-
ment of antibody formation (74% at 3 months vs 52%) when
compared to controls, which makes it particularly useful in
this high-risk patient population. There was, however, a 41%
rate of injection site pain compared to 19% in the standard
vaccine group.51 Thus, with improving vaccines and varied
approaches to administering the vaccine, our ability to
HBeAg (−)
HBV DNA 104copies/ml
(1900 IU)
HBV DNA <104copies/ml
(<1900 IU)
Consider liver biopsy
Consider liver biopsy
before initiating therapy
Abnormal ALT or significant inflammation or
fibrosis on biosis:
long-term therapy required;
adefovir, entacavir preferred to
lamivudine owing to resistance concerns
Normal ALT and/or minimal
inflammation/fibrosis on biopsy:
consider delaying therapy until closer
to renal transplant
Treat only those with significant
inflammation on biopsy
or peri-renal transplant
Figure 3 | Treatment algorithm for the HBeAg () hepatitis B patient.
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decrease the HBV transmission rate in patients with renal
disease will continue to improve. However, though it is
believed that immunity is lifelong, the CDC recommends
that HD patients have HBsAb titers checked on a yearly
basis such that booster vaccine can be administered if
necessary.
SUMMARY
There are no definitive therapeutic guidelines that outline
which patients to treat, with which agent, and for how long.
In fact, patients with chronic hepatitis B comprise such a
varied group of patients with various degrees of liver disease
(and function) that treatment indications and end points are
not yet clearly established. It is most likely that combination
therapy will replace monotherapy as the mainstay of
treatment. What remains to be further elucidated is which
drugs will be most efficacious, best tolerated, and associated
with the lowest rates of resistance. Additionally, timing of
initial therapy and duration of therapy need to be further
assessed. The role of HBV genotyping and resistance testing
also needs to be further explored. The recent FDA approval of
entecavir and the myriad of new products currently being
studied attest to the fact that this is a growing problem and
new data continue to support the use of therapy in a growing
number of patients, particularly those with renal disease,
both in the pre- and post-transplant settings.
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